Selective depletion of TAMs by targeting CSF1R using monoclonal antibodies or small molecule inhibitors has been shown to restrict CSF1R+ TAM accumulation in the TME, leading to reduced tumor growth in a number of mouse models (20–23). The gene discussed is CSF1R; the disease is neoplasm.